Efficacy of ranibizumab combined with retinal laser photocoagulation in patients with macular edema secondary to BRVO
10.3969/j.issn.1009-0754.2025.08.014
- VernacularTitle:雷珠单抗联合视网膜激光光凝术对视网膜分支静脉阻塞继发黄斑水肿患者的疗效观察
- Author:
Fengyun HU
1
;
Lian'e DING
;
Fenfen CHEN
;
Xiaoli CAO
;
Hai CHU
;
Kai MA
;
Chun DENG
Author Information
1. 230031 安徽 合肥,联勤保障部队第九○一医院
- Keywords:
Macular edema;
Retinal laser photocoagulation;
Treatment;
Efficacy
- From:
Journal of Navy Medicine
2025;46(8):816-820
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy of ranibizumab combined with retinal laser photocoagulation in patients with macular edema secondary to branch retinal vein occlusion(BRVO)and its impact on best-corrected visual acuity(BCVA)and central macular thickness(CMT).Methods A prospective analysis was conducted on 70 patients with secondary macular edema caused by BRVO who were admitted to the 901th Hospital of Joint Logistics Support Force from March 2019 to March 2023.According to the random number table method,the patients were assigned into study group or control group,with 35 cases in each group.The control group was treated with ranibizumab,while the study group was treated with ranibizumab and retinal laser photocoagulation.The efficacy,BCVA,CMT,intraocular pressure,adverse reactions,and 36-item short form health survey(SF-36)score were compared between the two groups.Results There was a significant difference in the efficacy between the two groups(Z=2.272,P<0.05),and the total effective rate of the study group was higher than that of the control group(P<0.05).The results of repeated measure ANOVA showed that CMT and intraocular pressure decreased significantly,while BCVA increased significantly in both groups after 3 months,6 months,and 12 months of treatment(P<0.05);moreover,these parameters in the study group were superior to those in the control group(P<0.05).There were no significant differences in the incidence of cataracts,transient intraocular pressure elevation,subconjunctival hemorrhage,retinal detachment,or the total incidence of adverse reactions between the two groups(P>0.05).After 12 months of treatment,the total score of SF-36 increased in both groups(P<0.05),and the difference value of total score of SF-36 in the study group was superior to that in the control group(P<0.05).Conclusion The combination of ranibizumab and retinal laser photocoagulation can achieve a good therapeutic effect on macular edema caused by BRVO.It can effectively improve BCVA,CMT and intraocular pressure,reduce the risk of adverse reactions,and enhance the quality of life.
